CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
New York Asthma & Allergy Society (NYAAS) Scientific Meetings
BioCryst will attend the 2026 New York Asthma & Allergy Society (NYAAS) Scientific Meetings on Sept 09, 2026.
Browse our archive of congress materials
Filter
Showing 140 Materials
-
Clinical Outcomes With Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
EAACI | 2026 | HAE -
Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
EAACI | 2026 | HAE -
Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE -
Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE -
Real-World Patient Characterization, Prior Long-Term Prophylactic Prescribing Patterns, and Treatment Outcomes for Adults on Berotralstat With Hereditary Angioedema in Japan
EAACI | 2026 | HAE -
Safety, Tolerability, Immunogenicity, and Pharmacokinetics of BCX17725: Single and Multiple Ascending Dose
SID | 2026 | NS -
Preclinical Characterization of BCX17725, a Potent Inhibitor of KLK5 and KLK14, for the Treatment of Netherton Syndrome
SID | 2026 | NS -
Dose optimization of berotralstat in pediatric patients with HAE via population PK modeling and simulation
ASCPT | 2026 | HAE